---
title: 'Industry Daily Summary: What Happened on November 14, 2026'
headline: China draws licensing interest for more novel biotech assets
description: The Cell and Gene Therapy Catapult has begun looking for a successor
  to chief executive Matthew Durdy.
url: https://thebench.bio/news/industry/2026-11-14
topic: industry
date: '2026-11-14'
covers:
- '2026-11-14'
date_published: '2026-11-14T12:01:43Z'
date_modified: '2026-11-15T00:01:33Z'
tags:
- Industry
sources: 2
publisher: TheBench.Bio
---

# Industry Daily Summary: What Happened on November 14, 2026

**China draws licensing interest for more novel biotech assets**

The Cell and Gene Therapy Catapult has begun looking for a successor to chief executive Matthew Durdy.

## Today in brief

A BioCentury-BayHelix summit analysis described a shift in buyer interest toward China-based biotech assets with potential to deliver novel therapeutic advances. [1] It compared that interest with earlier attention to lower-cost assets that might produce data faster. [1]

The Cell and Gene Therapy Catapult hired Coulter Partners to find a successor to chief executive Matthew Durdy, who plans to retire in June 2027. [2]

## China licensing interest shifts toward novel assets

A BioCentury-BayHelix summit analysis described a shift in licensing interest toward China-based assets with potential to offer valuable therapeutic advances, away from lower-cost assets that might deliver data faster. [1]

The review covered therapeutic-product deals involving a China-based biotech licensor and a licensee anywhere in the world, from January 1, 2023, through September 30, 2026. [1]

## Cell and Gene Therapy Catapult seeks Durdy’s successor

The Cell and Gene Therapy Catapult contracted executive-search firm Coulter Partners to find its next chief executive. [2] Durdy plans to retire in June 2027 after leading the organization for seven years and working there for 15. [2]

Durdy said the UK has moved from strong cell and gene therapy research with little related industry to developing and manufacturing therapies at home for patients. [2] The Catapult was established in 2012. [2]

## Sources

1. [China’s innovation moment sees a rise in first in class](<https://www.biocentury.com/article/661612/china-s-innovation-moment-sees-a-rise-in-first-in-class?utm_source=bc_rss&utm_medium=rss>), BioCentury, 2026-11-14
2. [Recruitment experts hired in search for new CGT Catapult chief](<https://pharmafile.com/appointments/recruitment-experts-hired-in-search-for-new-cgt-catapult-chief/>), Pharmafile, 2026-11-14

---

TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing.

[1]: <https://www.biocentury.com/article/661612/china-s-innovation-moment-sees-a-rise-in-first-in-class?utm_source=bc_rss&utm_medium=rss>
[2]: <https://pharmafile.com/appointments/recruitment-experts-hired-in-search-for-new-cgt-catapult-chief/>
